Considerable controversy still exists about when a patient has reached steady state after starting subcutaneous LMWH ... practice of capping the dose of dalteparin in the obese patient cannot ...

Drugs used in less than 5% of cases were subcutaneous fondaparinux (4.4%), subcutaneous dalteparin (0.3%), and i.v. enoxaparin (0.1%). The most common indications for anticoagulant use among the ...